Safety and Tolerability of the Treatment of Youth-Onset Type 2 Diabetes
Year: 2013
Type: article
Abstract: OBJECTIVE: Data related to the safety and tolerability of treatments for pediatric type 2 diabetes are limited. The TODAY clinical trial assessed severe adverse events (SAEs) and targeted nonsevere adverse events (AEs) before and after treatment failure, which was the primary outcome (PO). RESEARCH DESIGN AND METHODS: Obese 10- to 17-year-olds (N = 699) with type 2 diabetes for <2 years and hemoglobin A1c (A1C) ≤ 8% on metformin monotherapy were randomized to one of three treatments: metformin, metformin plus rosiglitazone (M + R), or metformin plus lifestyle program (M + L). Participants were followed for 2-6.5 years. RESULTS: Gastrointestinal (GI) disturbance was the most common AE (41%) and was lower in the M + R group (P = 0.018). Other common AEs included anemia (20% before PO, 14% after PO), abnormal liver transaminases (16, 15%), excessive weight gain (7, 9%), and psychological events (10, 18%); the AEs were similar across treatments. Permanent medication reductions/discontinuations occurred most often because of abnormal liver transaminases and were lowest in the M + R group (P = 0.005). Treatment-emergent SAEs were uncommon and similar across treatments. Most (98%) were unrelated or unlikely related to the study intervention. There were no deaths and only 18 targeted SAEs (diabetic ketoacidosis, n = 12; severe hypoglycemia, n = 5; lactic acidosis, n = 1). There were 62 pregnancies occurring in 45 participants, and 6 infants had congenital anomalies. CONCLUSIONS: The TODAY study represents extensive experience managing type 2 diabetes in youth and found that the three treatment approaches were generally safe and well tolerated. Adding rosiglitazone to metformin may reduce GI side effects and hepatotoxicity.
Source: Diabetes Care
DOI: 10.2337/dc12-2390
Author: TODAY Study Group
Institution: Washington University in St. Louis
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Funders: Massachusetts General Hospital, Yale University, Children's Hospital of Philadelphia, Children's Hospital Los Angeles, George Washington University, Washington University in St. Louis, Case Western Reserve University, National Institutes of Health, University of Oklahoma Health Sciences Center, University of Texas Health Science Center at San Antonio, University of Colorado Denver, National Institute of Diabetes and Digestive and Kidney Diseases, National Center for Research Resources, National Center for Advancing Translational Sciences, Children's Hospital of Pittsburgh
Awards: G1320905697, General Clinical Research Center, Management of Pediatric Type 2 Diabetes Mellitus, Multi-Center Study of the Treatment of T2DM in Youth, G149689038, Case Western Reserve University/Cleveland Clinic CTSA (UL1), G2427822680, Southern California Clinical and Translational Science Institute, G3314594697, G3394423889, Harvard Clinical and Translational Science Center (UL1), General Clinical Research Center, G3499161329, University of Pittsburgh Clinical and Translational Science Institute, G4012495729, G4113217758, Type 2 Diabetes in Youth: Beta Cell Preservation, Treatment Alternatives in Pediatric Type 2 Diabetes, TODAY2 Phase 2 (T2P2): Long-Term Post-Intervention Follow-Up, G523627176, G5308902211, G5318790011, Institutional Clinical and Translational Science Award, G5495349041, University of Pittsburgh Clinical and Translational Science Institute, General Clinical Research Center, G606898507, General Clinical Research Center, General Clinical Research Center, G6304731611, G6980401035, Washington University Institute of Clinical and Translational Sciences, G7382394668, G7635370081, Washington University Institute of Clinical and Translational Sciences (UL1), Yale University Clinical and Translational Science Award Program, General Clinical Research Center, Clinical and Translational Science Collaborative of Cleveland, G9000238543, The Washington University Center for Diabetes Translation Research, Colorado Clinical and Translational Science Institute (UL1)
OpenAlex ID: W159795859
